Artiva Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $202.9M
- Price
- $4.15
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.48%
- Volume
- 908.7K
About
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Quick stats
Shares outstanding48.9M
Computed float—
Float / sharesUnknown
Cash runway (months)51.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001817241
Websitehttps://www.artivabio.com
AI Summary
AI-generated1/30
criticalbearishclinical trial
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Artiva Biotherapeutics is discontinuing development of its lead asset AlloNK (AB-101), including canceling the planned Phase 3 pivotal trial, after longer-term data failed to show durable clinical response and two Grade 5 patient deaths occurred in its Phase 2a study.
The FDA asked Artiva to pause enrollment and dosing after a fatal leukoencephalopathy event assessed as likely fludarabine-associated neurotoxicity; a second sudden death was assessed as unrelated to study treatment.
The company is cutting its workforce by approximately 94% and evaluating strategic alternatives including merger, sale, asset licensing, or dissolution and liquidation, with Leerink Partners engaged as financial advisor.
Artiva reported approximately $319.1 million in preliminary, unaudited cash, cash equivalents and investments as of September 30, 2026.
Red flags
- lead asset discontinued; planned Phase 3 pivotal trial will not be initiated
- two Grade 5 (fatal) safety events in clinical study; FDA-ordered enrollment/dosing pause
- 94% workforce reduction
- strategic alternatives may include dissolution and liquidation; no assurance of any transaction
- preliminary cash figure is unaudited and subject to adjustment